[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2022004291A - Anticuerpos dirigidos a tirosina cinasa 3 relacionada con fms (flt3) y uso de los mismos. - Google Patents

Anticuerpos dirigidos a tirosina cinasa 3 relacionada con fms (flt3) y uso de los mismos.

Info

Publication number
MX2022004291A
MX2022004291A MX2022004291A MX2022004291A MX2022004291A MX 2022004291 A MX2022004291 A MX 2022004291A MX 2022004291 A MX2022004291 A MX 2022004291A MX 2022004291 A MX2022004291 A MX 2022004291A MX 2022004291 A MX2022004291 A MX 2022004291A
Authority
MX
Mexico
Prior art keywords
proteins
antibodies targeting
targeting flt3
pharmaceutical compositions
flt3
Prior art date
Application number
MX2022004291A
Other languages
English (en)
Inventor
Asya Grinberg
Hemanta Baruah
Gregory P Chang
Ann F Cheung
Zong Sean Juo
Thomas J Mcquade
Original Assignee
Dragonfly Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=75538063&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022004291(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc
Publication of MX2022004291A publication Critical patent/MX2022004291A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describen proteínas con dominios variables de cadena pesada y cadena ligera de anticuerpos que pueden emparejarse para formar un sitio de unión a antígeno dirigido a FLT3 en una célula, composiciones farmacéuticas que comprenden las proteínas y métodos terapéuticos que usan las proteínas y composiciones farmacéuticas, incluso para el tratamiento del cáncer.
MX2022004291A 2019-10-15 2020-10-14 Anticuerpos dirigidos a tirosina cinasa 3 relacionada con fms (flt3) y uso de los mismos. MX2022004291A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962915120P 2019-10-15 2019-10-15
PCT/US2020/055480 WO2021076554A1 (en) 2019-10-15 2020-10-14 Antibodies targeting flt3 and use thereof

Publications (1)

Publication Number Publication Date
MX2022004291A true MX2022004291A (es) 2022-05-10

Family

ID=75538063

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004291A MX2022004291A (es) 2019-10-15 2020-10-14 Anticuerpos dirigidos a tirosina cinasa 3 relacionada con fms (flt3) y uso de los mismos.

Country Status (16)

Country Link
US (1) US20240228628A9 (es)
EP (1) EP4045537A4 (es)
JP (1) JP2022551757A (es)
KR (1) KR20220082882A (es)
CN (1) CN115348972A (es)
AR (1) AR120222A1 (es)
AU (1) AU2020366000A1 (es)
BR (1) BR112022006817A2 (es)
CA (1) CA3153801A1 (es)
CL (1) CL2022000927A1 (es)
CO (1) CO2022004743A2 (es)
IL (1) IL292259A (es)
MX (1) MX2022004291A (es)
PE (1) PE20221256A1 (es)
TW (1) TW202124449A (es)
WO (1) WO2021076554A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117136071A (zh) * 2021-02-10 2023-11-28 悟境股份有限公司 多肽及其在治疗疾病中的用途
KR20240057457A (ko) * 2021-08-16 2024-05-02 헤모제닉스 파마슈티컬스 엘엘씨 항-flt3 항체, car, car t 세포 및 사용 방법
EP4444281A1 (en) * 2021-12-10 2024-10-16 Tubulis GmbH Novel flt3 antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof in combination with tyrosine kinase inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR071891A1 (es) * 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
NL2014108B1 (en) * 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
US10751422B2 (en) * 2015-03-09 2020-08-25 Agensys, Inc. Antibody drug conjugates (ADC) that bind to FLT3 proteins
WO2017011803A1 (en) * 2015-07-16 2017-01-19 Cellerant Therapeutics, Inc. Cysteine-substituted immunoglobulins
CA3062328A1 (en) * 2017-06-02 2018-12-06 Pfizer Inc. Chimeric antigen receptors targeting flt3
CN111247167A (zh) * 2017-06-02 2020-06-05 辉瑞公司 Flt3的特异性抗体及其用途

Also Published As

Publication number Publication date
CO2022004743A2 (es) 2022-07-08
AR120222A1 (es) 2022-02-02
AU2020366000A1 (en) 2022-05-12
BR112022006817A2 (pt) 2022-07-05
IL292259A (en) 2022-06-01
US20240228628A9 (en) 2024-07-11
EP4045537A4 (en) 2024-07-17
CL2022000927A1 (es) 2022-10-28
JP2022551757A (ja) 2022-12-13
CA3153801A1 (en) 2021-04-22
EP4045537A1 (en) 2022-08-24
CN115348972A (zh) 2022-11-15
PE20221256A1 (es) 2022-08-16
KR20220082882A (ko) 2022-06-17
TW202124449A (zh) 2021-07-01
WO2021076554A8 (en) 2022-04-21
US20240132598A1 (en) 2024-04-25
WO2021076554A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
MX2020008336A (es) Dominios variables de anticuerpos que se dirigen al receptor nkg2d.
MX2020008683A (es) Dominios variables de anticuerpo que se dirigen a cd33 y sus usos.
MX2024008677A (es) Conjugados de camptotecina.
JOP20200309A1 (ar) أجسام مضادة لـ il-11
EA201992590A1 (ru) Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
CY1122456T1 (el) Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου
MX2018015393A (es) Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo.
MX2020013468A (es) Anticuerpos il-11ra.
MX2022004291A (es) Anticuerpos dirigidos a tirosina cinasa 3 relacionada con fms (flt3) y uso de los mismos.
EA202091888A1 (ru) Вариабельные домены антител, нацеленные на рецептор nkg2d
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
MX2022005132A (es) Terapia combinada con formulaciones de anticuerpos anti-pvrig y anticuerpos anti-pd-1.
MX2022013882A (es) Anticuerpos dirigidos contra el miembro a de la familia de dominios de lectina tipo c 12 (clec12a) y uso de los mismos.
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
MX2023001556A (es) Anticuerpos que se dirigen a egfr y uso de los mismos.
MX2021007235A (es) Tubulisinas y conjugados de proteina-tubulisina.
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.
MX2018013484A (es) Nuevos anticuerpos anti-tnfrsf21 y modos de uso.
MX2024003913A (es) Anticuerpos dirigidos al receptor del factor activador de celulas b (baff-r) y uso de los mismos.
AR127897A1 (es) Anticuerpos dirigidos a 5t4 y usos de estos
CL2022002569A1 (es) Dominios variables de anticuerpos dirigidos al receptor nkg2d
EA202092279A1 (ru) Антитела к mica и/или micb и их применение